MolecularHealth has launched its TreatmentMap Targeted Panel, which covers 500 cancer-related genes, and the TreatmentMap Whole Exome test, which analyzes both somatic and germline mutations. Both tests also incorporate SafetyMap, a proprietary identification of drug target safety or resistance effects that uses the FDA’s Adverse Event Reporting System as an input for analysis. The tests are available for order in the US and Europe. MolecularHealth operates a CLIA-certified laboratory in The Woodlands, Texas.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.